Drug intelligence / Profile preview

SPARC1023 + carboplatin

Development stage: Unknown
Lead developer: Sun Pharma
Modality: Small Molecules
Administration: Intravenous

Overview

**SPARC1023 + carboplatin** is a combination regimen studied in phase I trials for advanced solid tumors. SPARC1023 is an investigational agent developed by Sun Pharma Advanced Research Company, administered as a 30-minute infusion, with dose escalation and pharmacokinetic profiling in combination with carboplatin, a well-established platinum-based chemotherapeutic. The study's primary aim was to establish the maximum tolerated dose (MTD) and pharmacokinetic profile for the combination. Carboplatin is a DNA-crosslinking agent that inhibits replication, while the exact molecular mechanism of SPARC1023 is not described in the available sources, though it is used in oncology settings.

Other names: SPARC1023SPARC-1023SPARC 1023

Targets

DNA

Beyond the preview

Go deeper on SPARC1023 + carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPARC1023 + carboplatin.

Explore the full profile